MANTLE CELL LYMPHOMA – A KILLER WITH A CHILD’S FACE

  • Miljan Krstić Center for Pathology, University Clinical Center Nis, 18000 Nis, Serbia; Department of Pathology, Faculty of Medicine, University of Nis, 18000 Nis, Serbia https://orcid.org/0000-0003-2634-3450
  • Slavica Stojnev Center for Pathology, University Clinical Center Nis, 18000 Nis, Serbia; Department of Pathology, Faculty of Medicine, University of Nis, 18000 Nis, Serbia https://orcid.org/0000-0001-5058-9720
  • Ivan Petković Clinic of Oncology, University Clinical Center Nis, 18000 Nis, Serbia; Department of Oncology, Faculty of Medicine, University of Nis, 18000 Nis, Serbia https://orcid.org/0000-0002-9110-4117
Keywords: Mantle cell lymphoma, diagnosis, pathology, immunohistochemistry, CyclinD1

Abstract


Mantle cell lymphoma (MCL) is a distinct type of non-Hodgkin lymphoma with very aggressive clinical behavior. Despite its bland morphology, MCL remains incurable and deadly disease, although several variants with more indolent clinical course have been recognized. This study aimed to comprehensively analyze pathological features of MCL in patients from Southearstern Serbia and to determine the frequency of this devastating disease in our population.  During the five-year period the diagnosis of MCL was established in 47 cases, which constitutes 10.3% of all newly diagnosed lymphomas in our Center for Pathology, University clinical center Nis. The majority of the patients were men, 72.3%, and the average patients’ age at the time of diagnosis was 66.1 years. Extranodal presentation was observed in 61.7%. Every fourth case of MCL was diagnosed on bone marrow biopsy. Oral cavity and gastrointestinal tract were equally represented as extranodal diagnostic location, with 17% respectively. MCL encompasses large spectrum of architectural patterns and cytological variants thus its diagnosis requires immunohistochemical analysis to CyclinD1 and SOX11 for correct diagnosis and distinction from other lymphoid neoplasms and reactive and hyperplastic conditions. Variant morphology of MCL may be easily confused with potentially curable or indolent lymphomas. Accurate and precise diagnosis of MCL may improve patients’ outcome through timely application of new and promising treatment strategies. Pathologist role in proper recognition and rapid diagnosis of MCL and its subtype, especially in biopsies from extranodal locations, including endoscopic biopsies, may contribute significantly to longer survival and better clinical outcome of the disease.  

 

Author Biography

Slavica Stojnev, Center for Pathology, University Clinical Center Nis, 18000 Nis, Serbia; Department of Pathology, Faculty of Medicine, University of Nis, 18000 Nis, Serbia

MD, PhD

References

Ahmed M, Zhang L, Nomie K, Lam L, Wang M. Gene mutations and actionable genetic lesions in mantle cell lymphoma. Oncotarget 2016;7(36):58638-48. [CrossRef] [PubMed]

Carvajal-Cuenca A, Sua LF, Silva NM, Pittaluga S, Royo C, Song JY, et al. In situ mantle cell lymphoma: clinical implications of an incidental finding with indolent clinical behavior. Haematologica 2012;97(2): 270-8. [CrossRef] [PubMed]

Clot G, Jares P, Gine E, Navarro A, Royo C, Pinyol M, et al. A gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome. Blood 2018;132:413-22. [CrossRef] [PubMed]

Dreyling M, Campo E, Hermine O, Jerkeman M, Le Gouill S, Rule S, et al; ESMO Guidelines Committee. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treat-ment and follow-up. Ann Oncol 2017;28(suppl 4): iv62-iv71. [CrossRef] [PubMed]

Fernàndez V, Salamero O, Espinet B, Solé F, Royo C, Navarro A, et al. Genomic and gene expression pro-filing defines indolent forms of mantle cell lymphoma. Cancer Res 2010;70(4):1408-18. [CrossRef] [PubMed]

Hirata N, Tominaga K, Ohta K, Kadouchi K, Okazaki H, Tanigawa T, et al. A case of mucosa-associated lymphoid tissue lymphoma forming multiple lympho-matous polyposis in the small intestine. World J Gastroenterol 2007;13(9):1453-7. [CrossRef] [PubMed]

Iwamuro M, Okada H, Kawahara Y, Shinagawa K, Morito T, Yoshino T, et al. Endoscopic features and prognoses of mantle cell lymphoma with gastro-intestinal involvement. World J Gastroenterol 2010; 16(37):4661-9. [CrossRef] [PubMed]

Jiang M, Bennani NN, Feldman AL. Lymphoma classi-fication update: B-cell non-Hodgkin lymphomas. Expert Rev Hematol 2017;10(5):405-15. [CrossRef] [PubMed]

Knezevic S. Primary mantle cell lymphoma of tonsil – Case report. Opsta medicina 2017;23(1-2):37-42. [CrossRef]

Mohammed A, Shariati F, Paranji N, Waghray N. Primary follicular lymphoma of colon: A case series and review of literature. Clin Case Rep 2021;9(7): e04486. [CrossRef] [PubMed]

Nassri R, Nassri A, Alkhasawneh A, de Souza Ribeiro B, Schey R. Colonic Mantle Cell Lymphoma with Multiple Lymphomatous Polyposis. GE Port J Gastro-enterol 2020;27(4):296-8. [CrossRef] [PubMed]

Petkovic I, Mihailovic D, Krstic M, Pejcic I, Vrbic S, Balic M. Primary mantle cell lymphoma of gastro-intestinal tract – a case report. Acta Medica Medianae 2012;51(3):41-6. [CrossRef]

Petkovic I, Stojnev S, Krstic M, Pejcic I, Vrbic S. Synchronous mantle cell lymphoma and prostate adenocarcinoma-is it just a coincidence? Vojno-sanitetski pregled 2016;73(11):1072-5. [CrossRef][PubMed]

Rašić DM, Knežević M, Terzić T, Vlajković G. Bilateral ocular panadnexal mass as initial presentation of systemic blastoid variant of mantle-cell lymphoma. Surv Ophthalmol 2017;62(1):83-8. [CrossRef] [PubMed]

Royo C, Salaverria I, Hartmann EM, Rosenwald A, Campo E, Beà S. The complex landscape of genetic alterations in mantle cell lymphoma. Semin Cancer Biol 2011;21(5):322-34. [CrossRef] [PubMed]

Salaverria I, Royo C, Carvajal-Cuenca A, Clot G, Navarro A, Valera A, et al. CCND2 rearrangements are the most frequent genetic events in cyclin D1(-) mantle cell lymphoma. Blood 2013;121:1394-402. [CrossRef] [PubMed]

Schlette E, Lai R, Onciu M, Doherty D, Bueso-Ramos C, Medeiros LJ. Leukemic mantle cell lymphoma: clinical and pathologic spectrum of twenty-three cases. Mod Pathol 2001;14(11):1133-40. [CrossRef] [PubMed

Shrestha R, Bhatt VR, Guru Murthy GS, Armitage JO. Clinicopathologic features and management of blastoid variant of mantle cell lymphoma. Leuk Lymphoma 2015;56(10):2759-67. [CrossRef] [PubMed]

Smedby KE, Sampson JN, Turner JJ, Slager SL, Maynadié M, Roman E, et al. Medical history, lifestyle, family history, and occupational risk factors for mantle cell lymphoma: the InterLymph Non-Hodgkin Lym-phoma Subtypes Project. J Natl Cancer Inst Monogr 2014;2014:76-86. [CrossRef] [PubMed]

Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon: IARC; 2017.

Todorovic M, Pavlovic M, Balint B, Kraguljac N, Mihaljevic B, Bogdanovic A, et al. Immunophenotypic profile and clinical characteristics in patients with advanced stage mantle cell lymphoma. Med Oncol 2007;24(4):413-8. [CrossRef] [PubMed]

Veloza L, Ribera-Cortada I, Campo E. Mantle cell lymphoma pathology update in the 2016 WHO classi-fication. Ann Lymphoma 2019;3. [CrossRef]

Yoshino T, Tanaka T, Sato Y. Differential diagnosis of chronic lymphocytic leukemia/small lymphocytic lym-phoma and other indolent lymphomas, including mantle cell lymphoma. J Clin Exp Hematop 2020; 60(4):124-9. [CrossRef] [PubMed]

Published
2022/04/12
Section
Original article